Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12–23 Months Following Meningococcal Vaccination
| Autor: | Brian D. Plikaytis, Olubukola T. Idoko, Ray Borrow, Helen Findlow, Marie-Pierre Preziosi, Daniel Holme, George M. Carlone, Samba O. Sow |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Microbiology (medical) The Meningitis Vaccine Project: The Development Licensure Introduction and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Enzyme-Linked Immunosorbent Assay Meningococcal Vaccines Meningococcal vaccine Neisseria meningitidis medicine.disease_cause Polysaccharide Vaccine IgG subclass Antigen Neisseria meningitidis Serogroup A Conjugate vaccine Tetanus Toxoid medicine Humans Haemophilus Vaccines meningococcal business.industry Meningitis Vaccine Project Infant vaccination medicine.disease Antibodies Bacterial Virology Vaccination Infectious Diseases Serologic and Safety Studies of a Group a Meningococcal Conjugate Vaccine Immunoglobulin G Africa Immunology Female business Meningitis |
| Zdroj: | Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/civ505 |
| Popis: | Sub-Saharan Africa has experienced epidemic cycles of Neisseria meningitidis group A (MenA) disease approximately every 5–10 years, with high disease incidence. One of the worst epidemics occurred in 1996, with greater than 250 000 recorded cases and 25 000 deaths [1]. The specific area of sub-Saharan Africa in which epidemics of MenA disease are frequent is termed the “meningitis belt” and was first described by Lapeyssonnie in 1963 [2] as spanning from Senegal in the west to Ethiopia in the east. Polysaccharide vaccines against MenA have been used in response to African outbreaks. These vaccines, however, are poorly immunogenic in children |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|